Navigation Links
Phase Genomics and Phyzen Co., Ltd. Announce Korean Distribution Partnership
Date:4/11/2017

Today, Phase Genomics and Phyzen Co., Ltd. have announced an exclusive partnership to deliver Phase Genomics’ Proximo™ Hi-C genome scaffolding service to the Korean market. The deal makes Phyzen the sole distributor of the service in all of South Korea.

“Phyzen’s experience and expertise in the Korean market will be a tremendous asset for further expanding our ability to deliver Proximo Hi-C to scientists and researchers around the world,” said Ivan Liachko, Phase Genomics’ co-founder and CEO. “With this partnership, biological research in South Korea is poised to make significant leaps forward.”

The Proximo Hi-C service builds on Hi-C-based genome scaffolding technology invented by members of the Phase Genomics founding team in 2013. Proximo has been used on hundreds of genome assemblies to date, including a goat genome recently published in Nature Genetics and highlighted in The Atlantic. This goat genome represents the most contiguous mammalian de novo assembly ever constructed, and the company notes many of its other customers are preparing manuscripts of their own on numerous plants and animals assembled with Proximo Hi-C.

“We have been impressed by the unparalleled capabilities of Phase Genomics’ Proximo Hi-C since we first saw its results,” said Kyoung-Dae Kang, CEO of Phyzen. “This technology will be of great importance to the Korean scientific community, and we’re thrilled to partner with Phase Genomics to be the exclusive providers of this service in South Korea.”

South Korean researchers may now contact Phyzen via their website to obtain more information about how to access Proximo Hi-C services. General information as well as instructions for obtaining the service outside South Korea can be found on Phase Genomics’ website.

ABOUT PHASE GENOMICS - Phase Genomics, Inc. is based in Seattle, WA and was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower researchers of all kinds with state-of-the-art genomic tools. The company serves academic and commercial researchers in diverse fields and industries.

Website: http://www.phasegenomics.com
Contact: info(at)phasegenomics(dot)com

ABOUT PHYZEN CO. LTD. - Phyzen Co., Ltd. is a bioinformatics and genomics service provider based in Seongnam, South Korea. The company was founded in 2013 by a team of genome scientists, bioinformaticians, and entrepreneurs. Phyzen closely works together with diverse researchers in university, government institute and private sector to provide the better solutions in genome research.

Website: http://www.phyzen.com
Contact: info(at)phyzen(dot)com

Read the full story at http://www.prweb.com/releases/2017/04/prweb14225455.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Self-assembled nanostructures enable a low-power phase-change memory for mobile electronic devices
3. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
4. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
5. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
6. irisnote Announces Successful Conclusion of Beta Test Phase
7. Risk Assessment and Mitigation in Phase I Trials in High Risk Compounds: A Continuously Developing Process, new life science webinar hosted by Xtalks
8. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
9. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
10. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
11. Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... two-dimensional representations of a complex biological network, a depiction of a system of ... mess,” said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):